Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lympho

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lympho

Item
http://www.wikidata.org/entity/Q34943963
Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases.Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: A case reportHigh-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European SocTreatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.The Safe Recipient of SSC Transplantation Prepared by Heat Shock With Busulfan Treatment in Mice
P2860

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lympho

Item
http://www.wikidata.org/entity/Q34943963
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@ast
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@en
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@nl
type
label
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@ast
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@en
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@nl
prefLabel
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@ast
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@en
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Phase 2 trial of high-dose rit ...... olvement by non-Hodgkin lympho
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932